Grant: Alliance Grants
University of Toronto
$144,700.00
Effects of psilocybin microdoses on serotonergic pathways and lipid signaling
EF 2023-24
Résumé
Psilocybin is the primary psychedelic component of hallucinogenic mushrooms. However, details on the mechanism of action specifically, the route of administration of psilocybin are not clear. While oral dosing is common practice with psilocybin, the effects of psilocybin in preclinical studies often varies depending on route of administration which leads to differences in onset of effects, the maximal effects, and the duration of the effect. Secondly, psilocybin research has focused on hallucinogenic doses with which effects are predominantly mediated by activation of serotonin 5-HT2A receptors (5-HT2AR) and inflammatory cytokines. Therefore, it is unknown whether microdoses of psilocybin may elicit differential sets of serotonin receptors in neurons, microglia, and astrocytes and alter brain signaling. This proposal has three major objectives: 1) to comprehensively examine expressions of serotonin receptor families and metabolites in the tryptophan-serotonin pathway after psilocybin injection through four routes of administrations (mouth, vein, abdominal cavity, brain), 2) to compare and contrast the neural networks affected by microdoses of hallucinogenic psilocybin and non-hallucinogenic 5-HT2A receptor agonist, lisuride, and 3) to investigate the effects of microdosing psilocybin on microglial and astrocytic markers of brain inflammation. These studies will build on current understanding of 5-HT2AR-mediated actions of psilocybin and provide critical discovery of novel additional mechanisms mediated by other serotonin receptors after microdosing psilocybin treatments.
Programme
Alliance Grants
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
576806-2022
Name nom
Bazinet, Richard RP
Department département
Nutritional Sciences
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2023
Competition year année de concours
2022
Award amount
144700
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1200
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Advancement of knowledge
Area of application fr
Avancement des connaissances
Research subject code
5300
Research subject group en
Molecular biology
Research subject group fr
Molecular biology
Research subject en
Biologie moléculaire
Research subject fr
Biologie moléculaire
Application title
Effects of psilocybin microdoses on serotonergic pathways and lipid signaling
Keyword
inflammatory pathways; lipidomics; psilocin metabolism; psilocybin; psychedelic therapy; serotonin; transcriptomics
Application summary
Psilocybin is the primary psychedelic component of hallucinogenic mushrooms. However, details on the mechanism of action specifically, the route of administration of psilocybin are not clear. While oral dosing is common practice with psilocybin, the effects of psilocybin in preclinical studies often varies depending on route of administration which leads to differences in onset of effects, the maximal effects, and the duration of the effect. Secondly, psilocybin research has focused on hallucinogenic doses with which effects are predominantly mediated by activation of serotonin 5-HT2A receptors (5-HT2AR) and inflammatory cytokines. Therefore, it is unknown whether microdoses of psilocybin may elicit differential sets of serotonin receptors in neurons, microglia, and astrocytes and alter brain signaling. This proposal has three major objectives: 1) to comprehensively examine expressions of serotonin receptor families and metabolites in the tryptophan-serotonin pathway after psilocybin injection through four routes of administrations (mouth, vein, abdominal cavity, brain), 2) to compare and contrast the neural networks affected by microdoses of hallucinogenic psilocybin and non-hallucinogenic 5-HT2A receptor agonist, lisuride, and 3) to investigate the effects of microdosing psilocybin on microglial and astrocytic markers of brain inflammation. These studies will build on current understanding of 5-HT2AR-mediated actions of psilocybin and provide critical discovery of novel additional mechanisms mediated by other serotonin receptors after microdosing psilocybin treatments.